savolitinib

FDA stop sign

Pharma

Hutchmed presents compelling data for 2 cancer drugs

Three months after an FDA rejection, Hutchmed presented promising data for two other oncology drugs.

Kevin Dunleavy Aug 9, 2022 11:09am

AstraZeneca

AZ, HutchMed get China nod for Orpathys for rare type of NSCLC

Jun 23, 2021 11:17am

AstraZeneca

Chi-Med's savolitinib helps Tagrisso-resistant patients

Mar 31, 2019 11:00am